During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and ...
HCB101, a novel Fc-based anti-SIRPα-CD47 fusion protein, has received orphan drug designation (ODD) from the FDA for the ...
She identified 2 primary frontiers for clinical investigation: the eradication of persistent cancer cells and the management ...
Targeted Oncology: The Richter transformation remains one of the most daunting diagnoses in hematology. Given your recent work with the BRUIN (NCT03740529)1 study, what are the red flags community ...
In an interview with Targeted Oncology, Erin Crane, MD, MPH, discusses PARP inhibitor restrictions in gynecologic oncology. Watch part 1 of the interview here.
Results showed the combination reduced the risk of death by 24% compared with chemotherapy alone, extending median OS to 18.2 ...
Brain metastases are far from a niche concern; with 100,000 to 200,000 cases diagnosed annually in the US, the scale of the ...
Selecting the Next Line of Therapy After SSA and PRRT in Progressive Pancreatic Neuroendocrine Tumor
This section focuses on the clinical decision making process following progression on lanreotide and lutetium Lu 177 dotatate ...
FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable ...
The FDA has approved a new tumor treating fields (TTF) therapy, Optune Pax, for the treatment of adult patients with locally ...
Cancer patients battling treatment-related hair loss often try biotin, but it rarely helps and can distort critical lab tests ...
In an interview on the first-in-human phase 1 study of gintemetostat, Saad Z. Usmani, MD, PhD, detailed the initial safety ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results